Gilead steals a march for hepatitis C drug application

Gilead ($GILD) has taken another big step forward with its hepatitis C drug sofosbuvir. The European Medicines Agency will provide an accelerated review of the treatment combined with ribavirin, which is shaping up as the first all-oral hepatitis C regimen up for a regulatory decision. While no guarantee that the EMA or any other agency will approve the drug, Gilead does have a shot at shaving two months off of the European review. And its odds are looking very good. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.